Skip to main content
. 2023 Mar 31;16(1):17–37. doi: 10.1016/j.jcmgh.2023.03.007

Figure 6.

Figure 6

Prevalence of AXL expression on macrophages in gut, peritoneum, bone marrow, and lymph node. (A) Representative immunofluorescence micrographs from AXL/CD68/DAPI stains of gut biopsies from control group (n = 4), ulcerative colitis (UC) (n = 5), Child-Pugh A (n = 7), Child-Pugh B (n = 5), and Child-Pugh C (n = 4). (B) Percentage of AXL+ macrophages lining the epithelial barrier relative to total population per HPF. (C) Schematic drawing of liver vessels with blood flow indicated and soluble AXL (sAXL) levels (pg/mL) in blood from portal and hepatic veins (n = 8). (D) AXL and MERTK expression of peritoneal macrophages from cirrhosis patients (pMACs, n = 23) in classical (CD14+CD16, class), intermediate (CD14++CD16+, inter), and non-classical (CD14++CD16++, non-class) subsets and monocyte-derived macrophages (M0-MDMs). (E) Representative immunofluorescence micrographs from AXL/CD68/DAPI stains of a lymph node from explant patient (Child-Pugh C) and control in follicular (F) and non-follicular (NF) regions. (F) Representative micrograph from AXL/CD68/DAPI stains of bone marrow from explant patient (Child-Pugh C) and control. Box plots showing median with 10–90 percentile and all points min-max. ∗P ≤ .05/∗∗P ≤ .01, Mann-Whitney and Kruskal-Wallis test. AF594, red; AF488, green; AF647, white; DAPI, blue; scale bar = 50 μm.